ArticleCurrent medicinal chemistry2026
Exploring Therapeutic Strategies against Monkeypox Virus Through Network Pharmacology and Bioinformatics Analysis.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe emergence of the monkeypox virus (MPXV) as a zoonotic threat has necessitated the development of effective treatments, particularly after it spread to regions outside of Central and Western Africa, such as the 2003 outbreak in the United States. Our groundbreaking study identifies CDK1 and TOP2A as key proteins in the pathogenesis of MPXV infection, utilizing network pharmacology to target these proteins for the first time. CDK1 and TOP2A, previously known for their roles in cell reprogramming, emerge as critical targets in our strategy to combat the virus.
methodsBy targeting CDK1 and TOP2A, proteins integral to cell reprogramming, with small molecules identified in our study, such as carnosic acid, rosmarinic acid, and coclaurine, we propose a novel method not only to inhibit the replication of the monkeypox virus but also to harness cellular plasticity for therapeutic purposes. The identification and targeting of these proteins with specific compounds disrupt the virus's life cycle and simultaneously enhance the efficiency of cell reprogramming.
resultsThis dual-action approach leverages the inherent plasticity of cellular reprogramming processes to combat the virus, showcasing a pioneering step in the use of regenerative medicine principles for antiviral strategies. Moreover, molecular docking and dynamic simulations strengthen our findings by demonstrating a strong binding affinity between TOP2A and CDK1, validating the synergistic effects of our identified small molecules.
conclusionOur research thus opens new avenues for addressing viral threats like monkeypox, utilizing the convergence of virology, network pharmacology, and cellular reprogramming to pave the way for innovative treatments.
Indexed as
Identifiers
40277070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.